BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

German biotech firm BioNTech and U.S. drugmaker Pfizer on Monday reported additional data from their experimental coronavirus vaccine that showed the vaccine was safe and induced an immune response in patients.

Additional data on Pfizer and BioNTech's potential coronavirus vaccine shows promise

Shares of BioNTech BNTX, +12.36% and Pfizer Inc. PFE, +1.82% both jumped in premarket trading on Monday after the companies said their experimental COVID-19 vaccine produced a T-cell response in people participating in a Phase 1/2 clinical trial in Germany.

BioNTech, Pfizer shares rally on preliminary data showing T-cell response from coronavirus vaccine candidate

Coronavirus vaccine partners Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) had incremental positive tidings concerning their mRNA vaccine candidate to combat SARS-CoV-2, the virus that causes COVID-19, sending shares of both companies sharply higher.

Pfizer-BioNTech Strike Deal With UK Government To Supply 30M Doses Of Coronavirus Vaccine

MAINZ, Germany and NEW YORK, July  20, 2020  (GLOBE NEWSWIRE) --  BioNTech SE  (Nasdaq: BNTX, “BioNTech” or “the Company”) and  Pfizer Inc . (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are available on an online preprint server at  medRxiv  and are concurrently undergoing scientific peer-review for potential publication.

Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

An effective vaccine is yet to be proven, however the U.K. has now secured access to up to 230 million vaccine doses.

Britain Secures 90 Million Doses Of Potential Coronavirus Vaccines From Pfizer, BioNTech & Valneva

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval.

Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2

AstraZeneca

Moderna

Novavax

GlaxoSmithKline

Inovio Pharmaceuticals

Sinovac Biotech

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Here Are All the COVID-19 Vaccines Currently in Clinical Testing

The 1 Number Healthcare Investors Should Consider When a Company Releases Study Results

A coronavirus vaccine has the potential to not only save countless lives, but also to mitigate trillions in economic damage.

Which Biotech Company Has the Most Promising Coronavirus Vaccine?

The biotech is reportedly in talks about supplying its COVID-19 vaccine candidates to the European Union.

Why BioNTech Stock Vaulted Higher Today

Johnson & Johnson

Sanofi

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna , Sanofi and Johnson & Johnson as well as biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

Gilead Sciences

The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy.

BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies

Regeneron Pharmaceuticals

Dozens are racing to develop a vaccine that could end the COVID-19 pandemic; so far, these companies look most likely to succeed.

4 Coronavirus Stocks to Watch This Summer

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna, Sanofi and Johnson & Johnson and biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines - sources

BioNTech SE (NASDAQ: BNTX) shares are trading higher after the company announced it would begin human trials of its coronavirus vaccine candidate in China.

Why BioNTech's Stock Is Trading Higher Today

Altimmune

IMV Inc

Sorrento Therapeutics Inc

Good news for Moderna was bad news for several of its rivals.

Why Several Coronavirus Vaccine Stocks Not Named Moderna Fell Today

Bloomin' Brands

Denny's

Brinker International

Ruth's Hospitality Group

Chains such as Outback Steakhouse, Chili's, Denny's, and Ruth's Chris were climbing on a positive vaccine trial.

Why Casual Dining Restaurant Stocks Were Gaining Today

Which investment wins in a battle between the two leaders in messenger RNA vaccines?

Better Coronavirus Vaccine Stock: BioNTech vs. Moderna

Pfizer's (PFE) shares jump after FDA grants fast track status to two coronavirus vaccine candidates

Pfizer/BioNTech's Coronavirus Vaccine Gets FDA Fast Track Tag

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

BioNTech: Promising Early COVID-19 Data, But Still A Long Way To Go

BioCryst Pharmaceuticals

Biosig Technologies Inc

CytoDyn Inc.

Eiger BioPharmaceuticals

Immunic Inc

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

The companies expect to manufacture 100 million doses by the end of 2021.

Pfizer and BioNTech Get "Fast Track" Designation for 2 COVID-19 Vaccines

The FDA handed the German biotech some good news for two coronavirus vaccine candidates.

Why BioNTech Stock Is Soaring Today

BioNTech stock surged Monday after the drug maker's Pfizer-partnered coronavirus vaccines nabbed a speedier development and review designation.
The post Pfizer, BioNTech Pop After Coronavirus Vaccine Nabs Speedy Review appeared first on Investor's Business Daily.

News for BioNTech SE Stock (BNTX)